

Table 2. Patient characteristics

Author, Year	Age at diagnosis	ECOG performance status	Charlson Score	Histology	Staging	Lymph node involvement	Surgical procedure	Post-operative complications	Adjuvant therapy
Ghebre et al., 2011	65-74 y.o.: 29.45%	0: 80.14% 1: 8.9%	0: 54.11% 1: 25.34%	Squamous cell carcinoma	I: 31% II: 33.33%	No involvement 73.57%	Radical vulvectomy only 17.81%	N/A	None 72.6% Chemotherapy
	75-84 y.o.: 47.95%	2: 1.37% 3: 4.48%	2+: 20.55%	97.95% Adenocarcinoma	III: 25.69% IV: 9.72%	Involvement 26.43%	Local excision only 4.11% Unilateral or bilateral inguinal LND 2.05%		only 0.68% Radiation only 10.27%
	85+ y.o.: 22.6%	4: 4.11%		2.05%			Radical vulvectomy+ inguinal LND 76.03%		Chemotherapy and radiation 16.44%
							Skin vulvectomy 3.8% Local excision 14.1%	N/A	N/A
							Hemivulvectomy 37.2% Radical vulvectomy 44.9%		
Bracchi et al., 2019	Mean 67.9 (SD 10.3)	N/A	Low 15.4% Intermediate 46.2% High 38.5%	Squamous carcinoma 96.2% Adenocarcinoma 3.8%	IA 14.1% IB 29.5% II 16.7% III 17.9% IV 7.7%	Positive 24.4%			
							Hysterectomy (50%), Oophorectomy (30%), Lymphadenectomy (20%)	N/A	N/A
Mullen et al., 2021	Median 74 years (range 65-97 years)	N/A	N/A	Endometrial, ovarian, cervical, vulvar, vaginal cancers	All stages included	N/A			
Gans et al., 2023	≥70 years	WHO ≥3 (12.3%)	Median 1.0 (IQR 1.0–2.0), Score ≥3 (23.7%)	N/A	I 63.2% II 6.1% III 25.4% IV 5.3%	N/A	Excision (84.2%), SN without IFL (44.7%), IFL or LN debulking (21.9%)	N/A	Adjuvant radiotherapy (21.1%) Neoadjuvant (chemo)radiotherapy (3.5%) Chemoradiotherapy without surgery (9.6%)
	Mean 79.7 (SD 6.8)								
Levine et al., 2023	N/A	N/A	N/A	N/A	N/A	Associated with increased complications	Radical vulvectomy with unilateral (30%) or bilateral (50%) lymphadenectomy	Unplanned readmission (12.9%), Wound disruption (8.3%), Deep surgical site infection (3.7%)	N/A
Delli Carpini et al., 2025	N/A	N/A	N/A	N/A	N/A	N/A	Radical vulvectomy (70%), Sentinel lymph node biopsy (30%)	Wound infection (20%), Dehiscence (15%), Lymphedema (25%), Lymphocele (10%)	Radiotherapy (30%) Chemotherapy (15%)